Key Takeaways
- On April 28, 2026, Gilead Sciences finalized its $7.8 billion purchase of Arcellx, securing complete ownership of anito-cel, a promising CAR T-cell therapy targeting multiple myeloma.
- The stock is revisiting breakout support from an 11-year cup base formation with a pivot point at $123.47, while one analyst projects a $173 target by year’s end — representing potential upside of 35%.
- GILD shares have dropped 8% this month but remain up 22% year-over-year; currently trading near $128.
- Technical indicators show RSI plunging to 27, the most oversold reading in over a year, with the 200-day moving average providing nearby support.
- The Arcellx transaction will decrease both GAAP and non-GAAP 2026 diluted EPS by $5.57–$5.67, though projections indicate accretive contributions starting in 2028, contingent on regulatory approval.
Gilead Sciences finalized its Arcellx purchase on April 28, delivering $115 cash per share alongside a contingent value right worth $5 per share. The transaction valued at approximately $7.8 billion in total equity.
This acquisition grants Gilead complete control over anitocabtagene autoleucel (anito-cel), an experimental BCMA-targeted CAR T-cell treatment designed for multiple myeloma patients. The companies had previously partnered through a collaborative arrangement involving Kite, Gilead’s cellular therapy division.
Taking full ownership of Arcellx allows Gilead to eliminate ongoing profit-sharing arrangements, milestone payments, and royalty commitments. This strategic consolidation enables more rapid decision-making around development timelines and market launch strategies.
The additional $5 CVR payment per share triggers only if anito-cel achieves cumulative worldwide sales of at least $6 billion between its launch date and December 31, 2029. While ambitious, this threshold demonstrates strong expectations for the treatment’s market performance.
Cindy Perettie, who leads Gilead’s Kite division, emphasized that priorities now shift toward “executing with speed and discipline” while preparing to deliver anito-cel to patients. Arcellx’s personnel and proprietary D-Domain BCMA binder platform will merge into Kite’s existing manufacturing capabilities and regulatory framework.
Financially, the acquisition will pressure Gilead’s GAAP and non-GAAP 2026 diluted earnings per share by $5.57 to $5.67. When acquired in-process R&D costs are excluded, the deal projects modest dilution through 2026 and 2027, transitioning to earnings accretion beginning in 2028 — dependent on anito-cel receiving FDA clearance.
Arcellx shares will be removed from Nasdaq Global Select Market trading following merger finalization.
Chart Analysis
Technically, GILD occupies a compelling position. Shares are retesting breakout territory from an 11-year cup base pattern at the $123.47 pivot level — a formation tracing back to bearish candle formations during June and July 2015.
Extended breakout patterns historically demonstrate improved success probabilities, making this retest particularly noteworthy. The stock’s RSI has collapsed to 27, marking its lowest point in at least twelve months and indicating severely oversold conditions. The 200-day simple moving average sits close by and previously provided support during both May and October of the prior year.
GILD has posted losses in eight of the past ten weeks, including an 8% April decline. Notably, both March and April selloffs occurred on lighter volume, which many technical traders interpret as a positive signal.
Biotech Sector Overview
The SPDR S&P Biotech ETF has advanced 9% in 2026, outperforming the broader healthcare sector’s 7% decline — making healthcare the weakest of eleven major S&P sectors. Meanwhile, the iShares Biotechnology ETF, which holds Gilead as its top position at nearly 8% of total assets, has generated returns below 1% year-to-date.
GILD shares have climbed 4% since January and posted 22% gains over the trailing twelve months despite recent weakness. A technical strategist has established a $173 year-end price objective, suggesting 35% appreciation potential from the current $128 level. The bullish scenario remains viable provided shares maintain support above $118.
Gilead concluded its Arcellx tender offer on April 28, with approximately 77.2% of outstanding Arcellx shares tendered into the transaction.
